Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Mesothelioma: early-phase trial registry
4 of 13 indexed Malignant Mesothelioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Malignant Mesothelioma: 13 US clinical trials tracked, 4 recruiting.
Malignant Mesothelioma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 2 of these trials.
Enrollment posture brief
Registry condition malignant-mesothelioma
OPEN 4 | RECR 31% | LATE 2 | EARLY 11 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)
Malignant Mesothelioma lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Mesothelioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Mesothelioma is recruiting below its size-band peers.
4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Mesothelioma research.
Alliance for Clinical Trials in Oncology accounts for 2 of 13 trials (15.4%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Malignant Mesothelioma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Malignant Mesothelioma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
NCT06566079
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06057935
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT03007030
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
David Bartlett, MD
NCT07192900
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Roswell Park Cancer Institute
NCT03678350
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
NCT00017186
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
St. Vincent Medical Center - Los Angeles
NCT00002475
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
NYU Langone Health
NCT00004033
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Jonsson Comprehensive Cancer Center
NCT00024076
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
Roswell Park Cancer Institute
NCT00003974
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Fox Chase Cancer Center
NCT00003263
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
NCT00005636
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Mesothelioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Mesothelioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Mesothelioma page
13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Malignant Mesothelioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Malignant Mesothelioma trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Mesothelioma condition card totals 13 registered trials; most-linked intervention recombinant interferon alfa; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.